213 related articles for article (PubMed ID: 21071691)
1. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.
Philipose S; Konya V; Sreckovic I; Marsche G; Lippe IT; Peskar BA; Heinemann A; Schuligoi R
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2416-23. PubMed ID: 21071691
[TBL] [Abstract][Full Text] [Related]
2. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function.
Iyú D; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
Platelets; 2010; 21(5):329-42. PubMed ID: 20433310
[TBL] [Abstract][Full Text] [Related]
3. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Glenn JR; White AE; Iyu D; Heptinstall S
Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
[TBL] [Abstract][Full Text] [Related]
4. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood.
Schober LJ; Khandoga AL; Dwivedi S; Penz SM; Maruyama T; Brandl R; Siess W
J Thromb Thrombolysis; 2011 Aug; 32(2):158-66. PubMed ID: 21424266
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors.
Petrucci G; De Cristofaro R; Rutella S; Ranelletti FO; Pocaterra D; Lancellotti S; Habib A; Patrono C; Rocca B
J Pharmacol Exp Ther; 2011 Feb; 336(2):391-402. PubMed ID: 21059804
[TBL] [Abstract][Full Text] [Related]
6. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
[TBL] [Abstract][Full Text] [Related]
7. Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors.
Konya V; Philipose S; Bálint Z; Olschewski A; Marsche G; Sturm EM; Schicho R; Peskar BA; Schuligoi R; Heinemann A
Eur J Immunol; 2011 Aug; 41(8):2379-89. PubMed ID: 21681739
[TBL] [Abstract][Full Text] [Related]
8. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.
Philipose S; Konya V; Lazarevic M; Pasterk LM; Marsche G; Frank S; Peskar BA; Heinemann A; Schuligoi R
PLoS One; 2012; 7(8):e40222. PubMed ID: 22870195
[TBL] [Abstract][Full Text] [Related]
9. PGE1 and PGE2 modify platelet function through different prostanoid receptors.
Iyú D; Jüttner M; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):9-16. PubMed ID: 21095237
[TBL] [Abstract][Full Text] [Related]
10. The EP3 Agonist Sulprostone Enhances Platelet Adhesion But Not Thrombus Formation Under Flow Conditions.
Pasterk L; Philipose S; Eller K; Marsche G; Heinemann A; Schuligoi R
Pharmacology; 2015; 96(3-4):137-43. PubMed ID: 26228833
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells.
Aso H; Ito S; Mori A; Morioka M; Suganuma N; Kondo M; Imaizumi K; Hasegawa Y
Am J Physiol Lung Cell Mol Physiol; 2012 Jan; 302(2):L266-73. PubMed ID: 22080750
[TBL] [Abstract][Full Text] [Related]
13. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative.
Yuk DY; Ryu CK; Hong JT; Chung KH; Kang WS; Kim Y; Yoo HS; Lee MK; Lee CK; Yun YP
Biochem Pharmacol; 2000 Oct; 60(7):1001-8. PubMed ID: 10974210
[TBL] [Abstract][Full Text] [Related]
15. The EP1/EP3 receptor agonist 17-pt-PGE
Theiler A; Konya V; Pasterk L; Maric J; Bärnthaler T; Lanz I; Platzer W; Schuligoi R; Heinemann A
Vascul Pharmacol; 2016 Dec; 87():180-189. PubMed ID: 27664754
[TBL] [Abstract][Full Text] [Related]
16. Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking.
Konya V; Üllen A; Kampitsch N; Theiler A; Philipose S; Parzmair GP; Marsche G; Peskar BA; Schuligoi R; Sattler W; Heinemann A
J Allergy Clin Immunol; 2013 Feb; 131(2):532-40.e1-2. PubMed ID: 22704539
[TBL] [Abstract][Full Text] [Related]
17. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
[TBL] [Abstract][Full Text] [Related]
18. Platelet alpha-granule secretion and its modification by SC-57101A, a GPIIb/IIIa antagonist.
Ogawa T; Sugidachi A; Otsuguro K; Isobe T; Asai F
Biochem Pharmacol; 2002 May; 63(10):1911-8. PubMed ID: 12034376
[TBL] [Abstract][Full Text] [Related]
19. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
